Management of DAAs Failure

More documents

Recommendations

Info

Protease inhibitor-Resistant Viruses are Progressively Replaced by WT- Sensitive Viruses after Rx Failures Lenz et al., J Hepatol 2015;62(5):1008-14.
Pts With NS5A RAVs (%) Durability of Treatment-Emergent NS5A RAVs After Virologic Failure • NS5A RAVs persisted in majority of pts for 96 wks 100 80 98 100 98 100 95 86 60 40 n/N = 20 0 62/ 63 58/ 58 42/ 43 VF Baseline FU-12 FU-24 FU-48 FU-96 45/ 45 Registry Study 52/ 55 50/ 58 Dvory-Sobol H, et al. EASL 2015. Abstract O059.
Page 2 and 3: Management of DAAs Failure Prof. Ga
Page 4 and 5: • HCV is an enveloped, positive-s
Page 6 and 7: Antiviral Resistance • Each patie
Page 8 and 9: All DAAs Can Select Resistant Varia
Page 10 and 11: Barrier to Resistance Low-barrier d
Page 13: NS5B RAV(S) • Sofosbuvir has a hi
Page 18 and 19: SVR12 (%) 24 Wks of LDV/SOF Retreat
Page 20 and 21: DAA Treatment Failure •Relapse or
Page 22 and 23: Treatment recommendations for retre
Page 24 and 25: A- Retreatment of patients with pre
Page 26 and 27: A- Retreatment of patients with pre
Page 28 and 29: Abstract ID: 849 Author: Ng T. et a
Page 30 and 31: Summary • Treatment-emergent RAV(

Management of DAAs Failure

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?